A number of legislative events are shaping the managed care landscape in 2022. These events range from broad reaching initiatives outlined in Biden’s Build Back Better Framework to proposals for promoting adoption of biosimilars to Medicare’s Advance Notice for the 2023 benefit year and discussions around Part D re-design as well as others.
As the United States and the world have seen firsthand how social determinants of health (SDOH) impact the mortality and morbidity of patients contracting the COVID-19 virus, addressing SDOH has become a national priority in health care. Organizations nationwide are increasingly looking to integrate SDOH and health equity into value-based strategies.
The oncology space is undergoing a tremendous amount of innovation, as novel new products and practices become available. But those treatments can do only so much good if oncologists aren’t using them. Precision's Christy Banach and Janet Serluco weigh in on the opportunity biopharma companies have to differentiate themselves from their competitors by addressing oncologists’ specific needs.
In 2021, NCQA and HL7 hosted the fifth annual Digital Quality Summit (DQS) that convened stakeholders within six distinct “tracks” – each track exploring a different subset of healthcare. PRECISIONvalue's Dominic Galante, MD, Jorge Font, MPH, and Maureen Hennessey, PhD, provided consultation to the Helmsley Charitable Trust, sponsors of the Track 6 “Rethinking Diabetes Care in the Digital Age.” Dr. Hennessey and Michael Barr, MD, of NCQA served as track co-leaders.
From federal lawmakers to pharmaceutical companies, plans, providers and other health care stakeholders, efforts are coalescing to address social determinants of health (SDOH). Initiatives are ramping up in response to COVID-19’s disparate impact on vulnerable populations and communities across the U.S. and include pharma collaborations with payers and health systems focusing on social determinants relevant to medication adherence and access.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
